Elicio's Lead Cancer Vaccine Misses Primary Endpoint in Phase 2 Trial
ELTX sits 24% above its 52-week low of $1.44.
Summary
Elicio's randomized Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) failed to hit its primary disease-free survival endpoint in the intent-to-treat population, with a hazard ratio of 0.85. That is a clear miss on the trial's main goal and undercuts the near-term probability of success for the lead program. Management points to an imbalance in baseline ctDNA positivity between arms as a possible confounder and notes consistent trends in pre-specified subgroups plus mKRAS T-cell responses that tracked with longer DFS. Safety was generally well tolerated. The company now plans to discuss a refined Phase 3 design with the FDA. This lands against a weak financial backdrop: the Q2 10-Q disclosed an $8.2 million quarterly net loss and substantial doubt about going concern, and the company already has a $100M at-the-market program in place. A small-cap biotech missing its primary endpoint has limited room to absorb the hit, and the next real datapoint is whatever Phase 3 plan the FDA talks produce.
At the time of this announcement, ELTX was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.6M. The 52-week trading range was $1.44 to $16.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.